8-KLeadership ChangesOther EventsExhibits & Filings

Zoetis Inc. 8-K Report, Executive Changes (Oct 18, 2021)

Filed October 18, 2021For Securities:ZTS

Summary

Zoetis Inc. (ZTS) announced a significant leadership transition within its Research & Development (R&D) division. Dr. Catherine Knupp, the current Executive Vice President and President of R&D, will retire effective December 31, 2021. Dr. Knupp will continue to support the company in an advisory role through February 28, 2022, to ensure a smooth handover of her responsibilities. To fill this critical role, Zoetis has appointed Dr. Robert J. Polzer as the new Executive Vice President and President of R&D, effective January 1, 2022. Dr. Polzer, currently the Senior Vice President of Global Therapeutics, brings extensive experience to lead the company's innovation efforts. This transition is a key event for investors to monitor as R&D leadership is crucial for Zoetis's future pipeline and product development.

Key Highlights

  • 1Dr. Catherine Knupp, EVP and President of R&D, is retiring effective December 31, 2021.
  • 2Dr. Knupp will serve as an advisor to assist with the transition from January 1, 2022, to February 28, 2022.
  • 3Dr. Robert J. Polzer has been appointed as the successor to Dr. Knupp, effective January 1, 2022.
  • 4Dr. Polzer currently holds the position of Senior Vice President of Global Therapeutics.
  • 5The company issued a press release on October 18, 2021, detailing these leadership changes.
  • 6The R&D function is critical for Zoetis's long-term growth and innovation.

Frequently Asked Questions

This 8-K filing is primarily to announce a change in executive leadership within Zoetis's Research & Development division, specifically the retirement of Dr. Catherine Knupp and the appointment of Dr. Robert J. Polzer as her successor.

Dr. Knupp will retire on December 31, 2021, but will remain with the company as an advisor until February 28, 2022, to facilitate a smooth transition of her duties to Dr. Polzer.

Dr. Polzer is currently the Senior Vice President of Global Therapeutics at Zoetis, indicating he has significant experience within the company's therapeutic areas and likely a deep understanding of its R&D operations.

This specific 8-K filing does not disclose any financial implications or changes to compensation arrangements for the departing or incoming executives. It focuses solely on the personnel changes and the transition plan.